Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04268836Not ApplicableUnknown

Vision Improvement for Patients With Age-Related Macular Degeneration

Role: lead

NCT04875234Not Yet Recruiting

Vision Improvement for Legally Blind Dry AMD Patients

Role: lead

NCT04693702Completed

Observational Study of Vision Improvement in Patients With Retinal Disorders

Role: lead

NCT04349254Completed

Observational Study of Vision Improvement in Late Stage Dry AMD Patients

Role: lead

All 4 trials loaded